Bavarian Nordic Share Price (0DPB)

The global vaccine group Gavi will buy 500,000 doses of Bavarian Nordic's mpox vaccine, its first purchase of the shot to help battle an outbreak in parts of Africa, the group said on Wednesday.

In 2024, there have been more than 25,000 suspected mpox cases and 723 deaths in Africa, mainly in the Democratic Republic of Congo, according to the World Health Organization, which has declared the outbreak a global health emergency.

Gavi, a public-private alliance which co-funds vaccine purchases for low-income countries, said it will spend up to $50 million on the plan, which includes the transportation, delivery and costs of administering the vaccines. The doses are due to be delivered this year.

First Doses of Bavarian Nordic’s Mpox Vaccine Now Arriving in the Democratic Republic of Congo

Vaccine donations from the European Commission, the U.S. government and Bavarian Nordic are now entering the DRC, the epicenter of the mpox outbreak

More than 250,000 doses to arrive over the next week, marking a crucial turning point in the combat against mpox in Africa

COPENHAGEN, Denmark, September 5, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that the first doses of its mpox vaccine, MVA-BN®, also known as JYNNEOS®, has arrived today in the Democratic Republic of Congo (DRC). Additional shipments to the DRC are planned within the next week adding to a total of more than 250,000 vaccines donated by the European Commission’s Health Emergency Preparedness and Response Authority (HERA), the U.S. government and Bavarian Nordic.

August 27, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that Singapore’s medicines regulatory authority, Health Sciences Authority (HSA), has approved JYNNEOS® (MVA-BN) for prevention of smallpox and mpox disease in adults 18 years of age and older determined to be at high risk for smallpox or mpox infection.

This marks the transition to a full approval for JYNNEOS in Singapore, where like in many other countries, the vaccine was made available under emergency use provisions to mitigate the last mpox outbreak.

“The recent declaration from the World Health Organization (WHO) that mpox again represents a Public Health Emergency of International Concern highlights the importance of removing barriers for access to approved vaccines all over the globe, and we are pleased to add Singapore to the list of countries where our smallpox and mpox vaccine is now approved. We continue to work with regulators in other countries as well to further broaden its access. Importantly, we are currently supporting the WHO Emergency Use Listing process and the Africa CDC to ensure rapid availability of the vaccine in the African continent, where prophylactic solutions are urgently needed,” said Paul Chaplin, President and Chief Executive Officer of Bavarian Nordic.

Just catching up on Mpox news and apart from Africa, Phillipines & Sweden, Asian countries with large populations such as China, Japan, India and South Korea are now reacting to the WHO concerns about it spreading, and are starting to monitor the potential increase of the virus.

These countries should get in contact with Bavarian Nordic (ASAP) and place orders so they can ramp up production. As at the moment it seems that they are the sole provider of the vaccine for the Clade 1 variant.

Https://www.nbcnewyork.com/news/business/money-report/bavarian-nordic-shares-pop-over-12-on-earnings-beat-bumper-mpox-vaccine-order/5727172/?amp=1